SCHEMBL23576901

SCHEMBL23576901

CNc1cccc(-c2ccc(NC(C)=O)cc2)c1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTT P42858 1/20 0.63
SMN1; SMN2 Q16637 1/20 0.63
L3MBTL1 Q9Y468 1/20 0.63
CYP17A1 P05093 1/20 0.59
CYP11B1 P15538 1/20 0.59
CYP11B2 P19099 1/20 0.59
HSD17B1 P14061 1/20 0.55
HSD17B2 P37059 1/20 0.55
PIP4K2A P48426 1/20 0.54
PIP4K2B P78356 1/20 0.54
CNR1 P21554 2/20 0.54
KMT2A Q03164 4/20 0.54
MEN1 O00255 3/20 0.54
NAPRT Q6XQN6 1/20 0.53
HSD17B10 Q99714 1/20 0.53
NQO2 P16083 2/20 0.53
SYK P43405 1/20 0.52
MAPT P10636 3/20 0.51
NPC1 O15118 1/20 0.51
RAB9A P51151 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8577619 0.91 SMN1; SMN2 (0.70) HTTSMN1; SMN2L3MBTL1CYP17A1CYP11B1
SCHEMBL3786463 0.82 NQO2 (0.73) SMN1; SMN2CYP17A1CYP11B1CYP11B2HSD17B1
SCHEMBL1487964 0.82 ALDH1A1 (0.66) SMN1; SMN2L3MBTL1KMT2AMEN1NAPRT
SCHEMBL28488286 0.82 TSHR (0.48) CYP17A1CYP11B1CYP11B2HSD17B1HSD17B2
SCHEMBL8265472 0.81 HSD17B10 (0.66) HTTSMN1; SMN2L3MBTL1HSD17B1HSD17B2
SCHEMBL12999591 0.81 NPC1 (0.69) HTTSMN1; SMN2L3MBTL1CYP17A1CYP11B1
Acetanilide SCHEMBL6693944 0.80 HSD17B10 (0.76) HTTSMN1; SMN2L3MBTL1KMT2AMEN1
SCHEMBL9293265 0.80 IDO1 (0.64) HTTSMN1; SMN2L3MBTL1CYP17A1CYP11B1
SCHEMBL969807 0.80 RAB9A (0.65) HTTSMN1; SMN2L3MBTL1CYP17A1CYP11B1
SCHEMBL4654909 0.80 ALDH1A1 (0.67) HTTSMN1; SMN2L3MBTL1CYP17A1CYP11B1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250361236-A9 DIACYLGLYCEROL KINASE MODULATING COMPOUNDS GILEAD SCIENCES INC (US) 2025-11-27 US disclosed
US-20240400568-A1 DIACYLGLYCEROL KINASE MODULATING COMPOUNDS GILEAD SCIENCES, INC. 2024-12-05 US disclosed
EP-4445902-A2 DIACYLGLYCEROL KINASE MODULATING COMPOUNDS Carna Biosciences, Inc. (JP) 2024-10-16 EP disclosed
EP-4081305-B1 DIACYLGLYCEROL KINASE MODULATING COMPOUNDS CARNA BIOSCIENCES INC (JP) 2024-09-18 EP disclosed
US-12054490-B2 Diacylglycerol kinase modulating compounds GILEAD SCIENCES, INC. (US) 2024-08-06 US disclosed
US-20240182476-A1 DIACYLGLYCEROL KINASE MODULATING COMPOUNDS GILEAD SCIENCES, INC. 2024-06-06 US disclosed
US-11845723-B2 Diacylglycerol kinase modulating compounds GILEAD SCIENCES, INC. (US) 2023-12-19 US disclosed
EP-4081305-A1 DIACYLGLYCEROL KINASE MODULATING COMPOUNDS Carna Biosciences, Inc. (JP) 2022-11-02 EP disclosed
US-20220324866-A1 DIACYLGLYCEROL KINASE MODULATING COMPOUNDS GILEAD SCIENCES, INC. 2022-10-13 US disclosed
US-20220324866-A1 DIACYLGLYCEROL KINASE MODULATING COMPOUNDS GILEAD SCIENCES, INC. 2022-10-13 US disclosed
WO-2021130638-A1 DIACYLGLYCEROL KINASE MODULATING COMPOUNDS CARNA BIOSCIENCES, INC. (JP) 2021-07-01 WO disclosed
WO-2021130638-A1 DIACYLGLYCEROL KINASE MODULATING COMPOUNDS CARNA BIOSCIENCES, INC. (JP) 2021-07-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240400568-A1 DIACYLGLYCEROL KINASE MODULATING COMPOUNDS DGKG, DGKB, DGKK HTT 4827/4885SMN1; SMN2 4737/4885L3MBTL1 2745/4885
US-20220324866-A1 DIACYLGLYCEROL KINASE MODULATING COMPOUNDS DGKG, DGKB, DGKK HTT 4827/4885SMN1; SMN2 4737/4885L3MBTL1 2745/4885
US-12054490-B2 Diacylglycerol kinase modulating compounds DGKG, DGKB, DGKK HTT 4827/4885SMN1; SMN2 4737/4885L3MBTL1 2745/4885
US-11845723-B2 Diacylglycerol kinase modulating compounds DGKG, DGKB, DGKK HTT 4827/4885SMN1; SMN2 4737/4885L3MBTL1 2745/4885
US-20240182476-A1 DIACYLGLYCEROL KINASE MODULATING COMPOUNDS DGKG, DGKB, DGKK HTT 4827/4885SMN1; SMN2 4737/4885L3MBTL1 2745/4885
US-20250361236-A9 DIACYLGLYCEROL KINASE MODULATING COMPOUNDS DGKG, DGKB, DGKK HTT 4827/4885SMN1; SMN2 4737/4885L3MBTL1 2745/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.